FDA Approval For Genentech's Avastin May Open Door To Broader Cancer Drug Standards

WASHINGTON (AP) - A drug made by Genentech received federal
approval on Friday to treat breast cancer, a decision that could
represent a major shift in standards for assessing the
effectiveness of cancer medicines.
Going against the recommendation of its advisory panel, the Food
and Drug Administration cleared Genentech's Avastin, which is
already approved for treating lung and colon cancer, based on
findings that it slowed tumor growth.
The agency has traditionally approved drugs for late-stage
cancer if they extended, or improved the quality of, patients'
lives. Avastin showed neither, according to Genentech's
application.
Wall Street analysts believe FDA's Avastin decision opens the
door for other cancer drugs to be approved for their
tumor-shrinking capabilities - a trend that worries some health
experts.

(Copyright 2008 by The Associated Press. All Rights Reserved.)


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WYMT CONTACT INFO 199 Black Gold Blvd. Hazard, KY 41701 606-436-5757 - switchboard 606-439-9968 - newsroom
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 15890782 - wkyt.com/a?a=15890782
Gray Television, Inc.